Merck’s Q4 and full-year 2022 earnings report

February 2, 2023

Share this article



Merck’s (NYSE: MRK) Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2% from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22% from full year 2021.

“2022 was an exceptional year for Merck, which is a testament to the profound impact our medicines and vaccines are having on patients globally,” said Robert M. Davis, chairman and chief executive officer. “I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically, commercially and operationally. Our science-led strategy is working as we continue to build a sustainable engine that will drive innovation and generate long-term value for patients and shareholders well into the next decade.”

Merck anticipates full-year 2023 worldwide sales to be between $57.2 billion and $58.7 billion.

Take a look at the infographic below for more details on Q4 and full-year 2022 results.

Download infographic